Broncus Holding (HKSE:02216) Interest Expense : HK$-1.34 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Broncus Holding's interest expense for the six months ended in Jun. 2024 was HK$ -0.40 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.34 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Broncus Holding's Operating Income for the six months ended in Jun. 2024 was HK$ -84.28 Mil. Broncus Holding's Interest Expense for the six months ended in Jun. 2024 was HK$ -0.40 Mil. Broncus Holding did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Broncus Holding Interest Expense Historical Data

The historical data trend for Broncus Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Interest Expense Chart

Broncus Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-4.04

-5.02

-1.33

-0.76

-1.27

Broncus Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial					-0.41	-0.36	-0.34	-0.94	-0.40

Broncus Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.34 Mil.

Broncus Holding (HKSE:02216) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Broncus Holding's Interest Expense for the six months ended in Jun. 2024 was HK$-0.40 Mil. Its Operating Income for the six months ended in Jun. 2024 was HK$-84.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was HK$6.11 Mil.

Broncus Holding's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Broncus Holding did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Broncus Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN

Website

https://www.broncus.com

Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.

Executives

Zi Zhenjun
Xin Nuo Tong Investment Limited	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Qm12 Limited	2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited	2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited	2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si
Zhe Jiang De Nuo Zi Ben Guan Li He Huo Qi Ye You Xian He Huo

Broncus Holding Headlines

No Headlines